Pharma Focus Europe

Exacis Biotherapeutics Grants Eterna Therapeutics an Option to License Up To Four Allogeneic Ipsc-derived NK And T Cell Therapies

Tuesday, October 18, 2022

Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced that it has signed an option agreement with Eterna Therapeutics Inc. ("Eterna") providing Eterna the right to license up to four off-the-shelf, iPSC derived NK cell and T cell cancer treatments to be produced using Exacis' proprietary mRNA-reprogrammed iPSCs that will be engineered with Exacis' mRNA-based gene editing platform. The option agreement provides Exacis and Eterna until December 31, 2022 to negotiate the license agreement. Terms include an upfront license fee, development and commercialization milestones, and single-digit royalties.

Exacis' non-viral platform uses mRNA-reprogrammed iPSCs engineered for stealthing and performance using Exacis' proprietary mRNA-based gene editing system including mRNA vector RiboSlice™ and nuclease NoveSlice™. The Exacis process avoids use of potentially harmful DNA and viruses by using mRNA.

Dr. Dimitri Goundis, Exacis' Chief Business Officer commented, "Exacis is committed to using its powerful platform to produce safe and effective immune cell therapies for cancer. Eterna is well positioned to rapidly advance products toward the clinic and patients".

Dr. Matt Angel, Eterna's Interim Chief Executive Officer added, "The opportunity to partner with Exacis and add next-generation mRNA-based NK and T cell therapies to our oncology portfolio is an important step in advancing Eterna's mission to realize the potential of cell engineering to provide patients with transformational new medicc

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva